萬孚生物(300482.SZ):百諾泰累計減持78.94萬股 減持計劃實施完畢
格隆匯11月13日丨萬孚生物(300482.SZ)公佈,近日,公司收到股東百諾泰出具的《股份減持的告知函》及其通知,截止到2019年11月12日,百諾泰已通過集中競價的方式減持其持有的公司無限售流通股約78.94萬股,此次減持計劃實施完畢;同時,百諾泰於近期完成了名稱變更等相關工商變更登記手續,並取得由建水縣市場監督管理局頒發的《營業執照》。
此次減持後,百諾泰持股比例由1.23%降至0.99%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.